Skip to content
Screener

Medtronic MDT Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

Abbott logo
AbbottABT
$47M-11.3%
TFX
TeleflexTFX
$16.99M+184%
Artivion logo
ArtivionAORT
$6.58M+33.6%
Insulet logo
InsuletPODD
$8.9M-16.0%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$1.79M
ITG
Integer HoldingsITGR
$20.76M-20.5%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$109.98B-3.9%
Enterprise value$137.24B-3.3%
P/E22.9×-1.7×
P/S-0.3×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNet.

The source filing: Medtronic’s 10-Q, filed February 24, 2026.

Filed
Feb 24, 2026, 4:18 PM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-011107
(in millions)Maturity by Fiscal YearJanuary 23, 2026April 25, 2025
4.200 percent twenty-year 2025 senior notes2046878
1.750 percent thirty-year 2019 senior notes20501,1711,142
1.625 percent thirty-year 2020 senior notes20511,1711,142
4.150 percent twenty-nine-year 2024 senior notes2054820800
Finance lease obligations2027 - 20415852
Debt discount, net2027 - 2054(58)(59)
Deferred financing costs2027 - 2054(118)(117)
Total long-term debt$27,880$25,642

Item 1. Financial Statements

FAQ

What is Medtronic's debt - unamortized discount (premium) and issuance costs, net?
Medtronic (MDT) reported debt - unamortized discount (premium) and issuance costs, net of $118M in Q4 2025.
How has Medtronic's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
Medtronic's debt - unamortized discount (premium) and issuance costs, net decreased by 2.5% year-over-year, from $121M to $118M.
What is the long-term trend for Medtronic's debt - unamortized discount (premium) and issuance costs, net?
Over 4 years (2021 to 2025), Medtronic's debt - unamortized discount (premium) and issuance costs, net has grown at a -1.6% compound annual growth rate (CAGR), from $125M to $117M.
What does debt - unamortized discount (premium) and issuance costs, net mean?
This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.

Ask your AI about Medtronic's debt - unamortized discount (premium) and issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude